Managing Risk of Gastric Cancer in Patients with Pathogenic Germline Variants in CDH1

Value of the Information & Strength of the Argument

The video provides valuable insights into the current clinical management of CDH1 carriers, particularly the shift from universal prophylactic gastrectomy to a more individualized approach based on endoscopic findings and family history. Dr. Stoffel’s argumentation is well-reasoned, acknowledging uncertainties and citing evidence from recent studies, such as those from the NIH cohort. She effectively uses analogies (e.g., prostate cancer) to explain the clinical dilemma and emphasizes the importance of specialized expertise in endoscopy and pathology. The discussion is balanced, presenting both the risks of surgery and the limitations of surveillance, and highlights ongoing research needs.

Scientific Rigor, Source Quality, Title Accuracy

The presentation demonstrates scientific rigor by referencing published studies and guidelines, including those from the NIH and international groups. Dr. Stoffel clearly distinguishes between her clinical experience and evidence from the literature. The title accurately reflects the content, which is focused on managing gastric cancer risk in CDH1 carriers. The video is part of a case conference series, and the speaker’s disclosures are mentioned. The sources cited are credible, though specific citations are not always explicitly named in the transcript. The adéquation between title and content is strong.

The title accurately reflects the content, which focuses on managing gastric cancer risk in CDH1 carriers.

8/10

The video features a recognized expert in hereditary GI cancer genetics (Dr. Elena Stoffel) and discusses current evidence and clinical practice, including references to published studies and guidelines. The content is nuanced, acknowledges uncertainties, and aligns with current medical knowledge.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction of the case: 30-year-old female with CDH1 variant, no family history of gastric cancer.
• 05:00Dr. Stoffel emphasizes the need for baseline endoscopy with extensive biopsies and expert pathology.
• 10:00Discussion on the prevalence of signet ring cells in CDH1 carriers and the analogy to prostate cancer.
• 15:00Debate on the value of imaging and endoscopic ultrasound; Dr. Stoffel states they have limited role.
• 20:00Explanation of the Cambridge protocol and the importance of separate biopsy bottles for different stomach regions.
• 25:00Discussion on the frequency of surveillance endoscopies, suggesting every 6 months after signet ring cells are found.
• 30:00Dr. Stoffel reviews the historical definition of hereditary diffuse gastric cancer and the evolution of guidelines.
• 35:00Presentation of risk estimates: lifetime gastric cancer risk may be 20-40%, lower than historical 60-80%.
• 40:00Discussion on the impact of prophylactic gastrectomy and the need for individualized decisions.
• 45:00Q&A: addressing questions about specific variants, pathology terminology, and the role of circulating tumor DNA.

• ICARE on Bluesky — Social media profile of the Inherited Cancer Registry, mentioned in the video description.
• ICARE on LinkedIn — LinkedIn page of the Inherited Cancer Registry, mentioned in the video description.

• NCCN Guidelines for Gastric Cancer — Referenced in the video as the basis for high-risk screening recommendations.
• NIH study on CDH1 risk (Jeremy Davis et al.) — Mentioned in the video as a source for updated risk estimates and surveillance recommendations.

• Historical guidelines recommending universal prophylactic gastrectomy — The video discusses the shift from older guidelines that recommended prophylactic gastrectomy for all CDH1 carriers to more nuanced approaches, reflecting evolving evidence.